Business
Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: Th
About this update from Cellyan Biotechnology Co., Ltd
[{"type":"text","content":"HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals:","length":506,"tagName":"p"},{"type":"text","content":"Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders;","length":186,"tagName":"p"},{"type":"text","content":"Proposal No. 2: The ratification of the appointment of Onestop Assurance PAC as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026;","length":186,"tagName":"p"},{"type":"text","content":"Proposal No. 3: The increase of the authorized share capital of the Company from US$100,000 divided into 100,000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001.","length":246,"tagName":"p"},{"type":"text","content":"Proposal No. 4: The re-designation and re-classification from ordinary shares of a single class to Class A ordinary shares and Class B ordinary shares.","length":151,"tagName":"p"},{"type":"text","content":"Proposal No. 5: The approval and implementation of the Reverse Share Split and Share Consolidation of the Company’s issued and outstanding Ordinary Shares.","length":155,"tagName":"p"},{"type":"text","content":"Proposal No. 6: The Company’s name be changed from “Hong Kong Pharma Digital Technology Holdings Limited” to “Cellyan Biotechnology Co., Ltd” and the Company’s foreign name be changed from “港药数字科技控股有限公司” to “生研生物公司”.","length":216,"tagName":"p"},{"type":"text","content":"Proposal No. 7: The fourth amended and restated memorandum and articles of association of the Company be adopted.","length":113,"tagName":"p"},{"type":"text","content":"Proposal No. 8: The repurchase by the Company of 7,150,000 Class A Ordinary Shares registered in the name of TUTU Business Services Limited and issue of Class B Ord...